{"id":6609,"date":"2019-11-26T16:31:19","date_gmt":"2019-11-26T11:01:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6609"},"modified":"2024-05-14T14:22:57","modified_gmt":"2024-05-14T08:52:57","slug":"recent-pharma-happenings-for-novartis-alexions-ferring-blackstone","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-alexions-ferring-blackstone","title":{"rendered":"Novartis buys Medicines; Blackstone Life Sciences and Ferring’s collaboration; Alexion’s Soliris (eculizumab) Approval;"},"content":{"rendered":"\n

Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market. <\/strong><\/p>\n\n\n\n

Under the terms of the deal, Novartis will pay USD 85 per share to the Medicines Company, a cholesterol drug developer, making the deal up to USD 9.7 Billion. The whole transaction will be completed by 2020. <\/p>\n\n\n\n

Around 95 million US adults age 20 or older have total cholesterol <\/a>levels higher than the normal levels i.e., 200mg\/dL. <\/p>\n\n\n\n

Inclisiran is a small interfering RNA therapy. The use of inclisiran for lowering down the blood cholesterol levels has still not been approved by any regulatory body. However, the results of the clinical study promise good results. The study Orion constitutes Phases III trials designed to evaluate the efficacy of the drug. The therapy lowers down the lower low-density lipoprotein (LDL) cholesterol \u2013 also known as LDL-C or bad cholesterol.<\/p>\n\n\n\n

Blackstone Life Sciences and Ferring Pharmaceuticals have\ncollaborated to jointly develop Ferring\u2019s late-stage bladder cancer therapy\ncandidate investing USD 570 Mn. <\/strong><\/h3>\n\n\n\n

Under the terms of the agreement, Blackstone has agreed to invest an amount of USD 400 Million while Ferring will invest up to USD 170 Million. <\/p>\n\n\n\n

The joint agreement will help the manufacturing and\ncommercialization of the drug, nadogaragene firadenovec and help secure the\nglobal rights. Upon the approval, FerGene, a new subsidiary of Ferring will\nhave the sole market authorization. <\/p>\n\n\n\n

The gene therapy is indicated for high-grade, Bacillus Calmette-Gu\u00e9rin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). Currently, the drug is in Phase III clinical trials. <\/p>\n\n\n\n

The main treatments for when the cancer cells are found only\nin the bladder’s inner lining (non-muscle- invasive bladder cancer) are\nsurgery, immunotherapy, and intravesical chemotherapy. Surgery\u2014on its own or\ncombined with other treatments\u2014is used in most cases.<\/p>\n\n\n\n

Other pharma players like Sesen Bio, Altor BioScience, TARIS Biomedical, and many more are advancing the Non-Muscle Invasive Bladder Cancer <\/a>(NMIBC) treatment market. <\/p>\n\n\n\n

Alexion Pharmaceuticals has recently received a nod from\nJapan\u2019s Health, Labour and Welfare Ministry (MHLW) for its drug Soliris (eculizumab).<\/strong><\/h3>\n\n\n\n

The drug has received the recommendation for the expanded\nuse to prevent relapse in anti-aquaporin-4 (AQP4) antibody-positive\nneuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica.<\/p>\n\n\n\n

The drug is the first drug to receive approval in Japan. The trials PREVENT revealed promising results of the drug to prolong time to the first relapse and reduce relapse risk. However, the drug is already approved to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults and atypical hemolytic uremic syndrome (aHUS) in children.<\/p>\n\n\n\n

At present, there exists no cure for Neuromyelitis Optica (NMO) and the existing treatment regimen revolves around relieving symptoms and prevention of frequent recurrences.<\/p>\n\n\n\n

Key players, such as Alexion Pharma, Chugai Pharmaceutical\/ Roche, and Viela Bio are involved in developing therapies for NMOSD. The launch of emerging therapy, such as Soliris (Alexion Pharma), Satralizumab (SA237) (Chugai Pharmaceutical\/ Roche) and MEDI-551 (Viela Bio) will significantly impact the NMOSD market <\/a>during the study period (2016-2027).<\/p>\n","protected":false},"excerpt":{"rendered":"

Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market. Under the terms of the deal, Novartis will pay USD 85 per share to the Medicines Company, a cholesterol drug developer, making the deal up to USD 9.7 Billion. […]<\/p>\n","protected":false},"author":1,"featured_media":6611,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2028,17835,2680,2867,17839,17440,349,17842,17308,17838,423,639,5789,524,17841,17651,1567,17836,17840],"industry":[17225],"therapeutic_areas":[17227,17245,17228,17234],"class_list":["post-6609","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alexion-pharmaceuticals","tag-altor-bioscience","tag-blackstone-life-sciences","tag-cholesterol","tag-chugai-pharmaceutical","tag-ferring-pharmaceuticals","tag-latest-pharma-news","tag-medi-551","tag-neuromyelitis-optica","tag-nmosd-market","tag-novartis","tag-pharma-news","tag-recent-pharma-news","tag-roche","tag-satralizumab","tag-sesen-bio","tag-soliris","tag-taris-biomedical","tag-viela-bio","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nPharma News | Novartis, Blackstone, Ferring Pharma, Alexion<\/title>\n<meta name=\"description\" content=\"Novartis buys Medicines; Blackstone Life Sciences and Ferring's collaboration; Alexion's Soliris (eculizumab) Approval;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-alexions-ferring-blackstone\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Novartis, Blackstone, Ferring Pharma, Alexion\" \/>\n<meta property=\"og:description\" content=\"Novartis buys Medicines; Blackstone Life Sciences and Ferring's collaboration; Alexion's Soliris (eculizumab) Approval;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-alexions-ferring-blackstone\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-26T11:01:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-14T08:52:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170341\/Pharma-News-26-Nov.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Novartis, Blackstone, Ferring Pharma, Alexion","description":"Novartis buys Medicines; Blackstone Life Sciences and Ferring's collaboration; Alexion's Soliris (eculizumab) Approval;","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-alexions-ferring-blackstone","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Novartis, Blackstone, Ferring Pharma, Alexion","og_description":"Novartis buys Medicines; Blackstone Life Sciences and Ferring's collaboration; Alexion's Soliris (eculizumab) Approval;","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-alexions-ferring-blackstone","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-11-26T11:01:19+00:00","article_modified_time":"2024-05-14T08:52:57+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170341\/Pharma-News-26-Nov.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-alexions-ferring-blackstone","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-alexions-ferring-blackstone","name":"Pharma News | Novartis, Blackstone, Ferring Pharma, Alexion","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-alexions-ferring-blackstone#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-alexions-ferring-blackstone#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170341\/Pharma-News-26-Nov.jpg","datePublished":"2019-11-26T11:01:19+00:00","dateModified":"2024-05-14T08:52:57+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Novartis buys Medicines; Blackstone Life Sciences and Ferring's collaboration; Alexion's Soliris (eculizumab) Approval;","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-alexions-ferring-blackstone"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis-alexions-ferring-blackstone#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170341\/Pharma-News-26-Nov.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170341\/Pharma-News-26-Nov.jpg","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170341\/Pharma-News-26-Nov.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alexion Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Altor BioScience<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Blackstone Life Sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cholesterol<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chugai Pharmaceutical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ferring Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MEDI-551<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neuromyelitis Optica<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NMOSD Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Satralizumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sesen Bio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Soliris<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TARIS Biomedical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Viela Bio<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alexion Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Altor BioScience<\/span>","<span class=\"advgb-post-tax-term\">Blackstone Life Sciences<\/span>","<span class=\"advgb-post-tax-term\">cholesterol<\/span>","<span class=\"advgb-post-tax-term\">Chugai Pharmaceutical<\/span>","<span class=\"advgb-post-tax-term\">Ferring Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">MEDI-551<\/span>","<span class=\"advgb-post-tax-term\">Neuromyelitis Optica<\/span>","<span class=\"advgb-post-tax-term\">NMOSD Market<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Satralizumab<\/span>","<span class=\"advgb-post-tax-term\">Sesen Bio<\/span>","<span class=\"advgb-post-tax-term\">Soliris<\/span>","<span class=\"advgb-post-tax-term\">TARIS Biomedical<\/span>","<span class=\"advgb-post-tax-term\">Viela Bio<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Nov 26, 2019","modified":"Updated on May 14, 2024"},"absolute_dates_time":{"created":"Posted on Nov 26, 2019 4:31 pm","modified":"Updated on May 14, 2024 2:22 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6609"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6609\/revisions"}],"predecessor-version":[{"id":28010,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6609\/revisions\/28010"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6611"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6609"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6609"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}